LEADER 03379nam  22006135  450 
001 9910300204503321
005 20200701171108.0
010   $a3-319-09788-1
024 7 $a10.1007/978-3-319-09788-6
035   $a(CKB)3710000000262062
035   $a(EBL)1966890
035   $a(OCoLC)908086352
035   $a(SSID)ssj0001372516
035   $a(PQKBManifestationID)11732688
035   $a(PQKBTitleCode)TC0001372516
035   $a(PQKBWorkID)11304093
035   $a(PQKB)10828794
035   $a(DE-He213)978-3-319-09788-6
035   $a(MiAaPQ)EBC1966890
035   $a(PPN)182096378
035   $a(EXLCZ)993710000000262062
100   $a20141016d2015      u|             0
101 0 $aeng
135   $aur|n|---|||||
181   $ctxt
182   $cc
183   $acr
200 10$aACEi and ARBS in Hypertension and Heart Failure$b[electronic resource] /$fedited by Pasquale Perrone Filardi
205   $a1st ed. 2015.
210  1$aCham :$cSpringer International Publishing :$cImprint: Springer,$d2015.
215   $a1 online resource (160 p.)
225 1 $aCurrent Cardiovascular Therapy ;$v5
300   $aDescription based upon print version of record.
311   $a3-319-09787-3 
320   $aIncludes bibliographical references and index.
327   $aPathogenetic mechanisms of RAS involvement in cardiovascular diseases -- Antiotensin converting enzyme inhibitors and at1 antagonists for treatment of hypertension.- Renin angiotensin system antagonism in heart failure -- Impact of co-morbidities on RAS inhibitors choice in hypertensive and heart failure patients -- Target organ damage and RAS blockade.
330   $aThis book summarizes how the renin angiotensin system is implicated in the progression of atherosclerotic disease as well as of left ventricular dysfunction and reviews the action of angiotensin converting enzyme inhibitors and AT1 receptor antagonists on reducing morbidity and mortality in patients with left ventricular dysfunction or in those at high cardiovascular risk with preserved ventricular function. ACEi and ARBS in Hypertension and Heart Failure is a highly practical reference reviewing the evidence and providing a rationale for the appropriate use of RAS antagonists in cardiovascular diseases. It is written in an easy-to-follow format and with many illustrations to aid clarity and the assimilation of information. Each chapter is written by established authorities in their fields who are also experienced in explaining often complex concepts. The result is a unique book which is not only comprehensive but also clear and useful for the busy medical practitioner.
410  0$aCurrent Cardiovascular Therapy ;$v5
606   $aCardiology
606   $aPharmacotherapy
606   $aCardiology$3https://scigraph.springernature.com/ontologies/product-market-codes/H33037
606   $aPharmacotherapy$3https://scigraph.springernature.com/ontologies/product-market-codes/H69000
615  0$aCardiology.
615  0$aPharmacotherapy.
615 14$aCardiology.
615 24$aPharmacotherapy.
676   $a610
676   $a615.1
676   $a616.12
702   $aPerrone Filardi$b Pasquale$4edt$4http://id.loc.gov/vocabulary/relators/edt
906   $aBOOK
912   $a9910300204503321
996   $aACEi and ARBS in Hypertension and Heart Failure$91759316
997   $aUNINA